News

latest corporate presentation

Latest Summary Corporate Presentation

November 2023

View Presentation
07 Jun 2023 PR Newswire Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
31 May 2023 PR Newswire Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
31 May 2023 Yahoo Finance Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
30 Mar 2023 PR Newswire Actinogen presents positive Phase 2a Xanamem data at AD/PD™ Alzheimer’s and Parkinson’s diseases conference
01 Mar 2023 Biotech Daily Actinogen Appoints Nicki Vasquez Non-Executive Director
01 Feb 2023 Biotech Daily Actinogen Appoints Dr Dana Hilt CMO
22 Dec 2022 Biotech Daily FDA Okays Actinogen 6-Months Xanamem Phase IIb Alzheimer’s Trial
22 Dec 2022 Seeking Alpha FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
22 Dec 2022 PR Newswire FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
22 Dec 2022 MarketWatch FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
22 Dec 2022 Yahoo FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
22 Dec 2022 The Market Herald Actinogen Medical (ASX:ACW) receives FDA approval for six-month phase 2b Alzheimer trial
22 Dec 2022 BioSpace FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
15 Dec 2022 Yahoo Finance Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
15 Dec 2022 Daily Bulletin Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
15 Dec 2022 BioPharma APAC Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
14 Dec 2022 PR Newswire Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
14 Dec 2022 BioSpace Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
08 Dec 2022 Biotech Daily Actinogen Treats First Xanamem Depression Patient
25 Nov 2022 Biotech Daily Dr Boreham’s Crucible: Actinogen Medical
21 Oct 2022 Yahoo Finance Actinogen Medical: re-initiation — Cognitive enhancer targeting key diseases
19 Oct 2022 Stockhead Alzheimer’s drug no longer a moonshot as race heats up, ASX-listed Actinogen in the running
19 Oct 2022 FN Arena Australian Broker Call *Extra* Edition – Oct 19, 2022
12 Oct 2022 Outsourcing-Pharma.com “Significant Step Forward” for Actinogen’s Alzheimer’s treatment
11 Oct 2022 EIN Presswire Actinogen Medical (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer’s Disease (AD) patients
11 Oct 2022 BioWorld Biomarker analysis yields clinical benefit for Actinogen’s Xanamem in Alzheimer’s disease
10 Oct 2022 The Market Herald Actinogen Medical (ASX:ACW) finds positive results in phase 2A trial of Xanamem on Alzheimers
10 Oct 2022 BioSpace Clinical Catch-Up: Actinogen, Applied Therapeutics, BrainStorm, Immatics, and More
10 Oct 2022 Labiotech.eu Positive data indicates likely therapeutic effect of Alzheimer’s drug
10 Oct 2022 Biotech Daily Actinogen Xanamem Alzheimer’s Biomarker Effect
10 Oct 2022 The Motley Fool Why Actinogen, Core Lithium, Fortescue, and Galileo Mining shares are pushing higher
10 Oct 2022 The Motley Fool Guess which ASX biotech share just rocketed 56% on new Alzheimer’s drug trial results
10 Oct 2022 Market Screener Actinogen Medical Validates Efficacy of Alzheimer’s Disease Therapy; Shares Surge 30%
10 Oct 2022 ShareCafe Stocks of the Hour: HLX, ACW, GAL
10 Oct 2022 Market Index Actinogen up 30% on strong Alzheimer’s trial results, says Xanamem product can slow progression
10 Oct 2022 PR Newswire Actinogen Medical Limited (ACW) announces large Xanamem therapeutic effect in early-stage Alzheimer’s Disease (AD) patients
29 Sep 2022 Stocks Down Under Actinogen Medical (ASX: ACW): Good news on phase 2 trials can catapult this stock
14 Jul 2022 Mirage News Actinogen confirms Alzheimer’s disease biomarker study timing and design
27 Jun 2022 FN Arena Australian Broker Call *Extra* Edition – Jun 27, 2022 | Bell Potter initiates coverage on Australian drug developer Actinogen Medical
14 Jun 2022 The Market Herald Actinogen Medical (ASX:ACW) announces phase two trial designs for AD & MDD
14 Jun 2022 Biotech Daily Actinogen Medical Plans Xanamem For Alzheimer’s, Depression Phase II Trials
14 Jun 2022 The Sentiment Why one contentious FDA drug approval is good news for Actinogen Medical
14 Jun 2022 IQ Stock Actinogen Announces Phase 2 Trials in Alzheimer’s Disease and Depression
14 Jun 2022 Global Newswire Actinogen Announces Phase 2 Trials in Alzheimer’s Disease and Depression
14 Jun 2022 Yahoo Finance Actinogen Announces Phase 2 Trials in Alzheimer’s Disease and Depression
14 Jun 2022 Biospace Actinogen Announces Phase 2 Trials in Alzheimer’s Disease and Depression
04 May 2022 The Market Herald Actinogen (ASX:ACW) prioritises Alzheimers disease and depression trials
04 May 2022 Market Index Actinogen reassesses its priorities: Clinical programs refocus on cognition
02 May 2022 Aged Care Insite Is Xanamem the Alzheimer’s breakthrough we’ve all been waiting for?
28 Apr 2022 Eminetra Australia Positive test results for Alzheimer’s drug Xanamem
28 Apr 2022 TechInvest Actinogen announces positive XanaMIA Part A trial
28 Apr 2022 Aged Care News Millions could benefit after breakthrough Alzheimer’s treatment trial by Aussie biotech
28 Apr 2022 Hospital and Healthcare Positive trial results for Alzheimer’s drug Xanamem
27 Apr 2022 Biotech Daily Actinogen XanaMIA Phase 1B Part A Trial Meets Endpoints
27 Apr 2022 The Sentiment New trial results from Actinogen hold promise for Alzheimer’s treatment
27 Apr 2022 The Market Herald Actinogen Medical (ASX:ACW) reports positive XanaMIA Part A trial topline results
27 Apr 2022 Kalkine Media Actinogen gets upbeat results from Xanamem trial for Alzheimer’s treatment
27 Apr 2022 Mirage News Millions worldwide could benefit after breakthrough trial in treatment for Alzheimer’s
27 Apr 2022 Australian Associated Press Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s
27 Apr 2022 news.com.au Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s
27 Apr 2022 The Australian Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s
27 Apr 2022 The National Tribune Millions worldwide could benefit after breakthrough trial in treatment for Alzheimer’s
27 Apr 2022 Actinogen Media Release: Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s by Aussie biotech Actinogen
26 Apr 2022 Clinical Trials Arena Pipeline Moves: Actinogen makes strides in mild cognitive impairment
11 Feb 2022 The Market Herald Actinogen Medical (ASX:ACW) advances Alzheimer’s treatment
09 Feb 2022 The Sentiment Actinogen appoints leading researchers to conduct Phase 2 trials for treatment of Fragile X Syndrome
09 Feb 2022 The Market Herald Actinogen Medical (ASX:ACW) locks in trial manager for FXS phase-two study
09 Feb 2022 Biotech Daily Worldwide To Manage Xanamem Fragile X Trial
22 Dec 2021 Stockhead Healthcare has been a hot sector. Here are the top ASX biotech stocks in 2021. Best performing ASX biotechs in 2021.
07 Dec 2021 The Market Herald Actinogen Medical (ASX:ACW) partners with Oxford University
07 Dec 2021 Stockhead ASX Health Stocks: Neuren stock price up 100pc on positive Phase 3 results In other ASX health news this morning: Actinogen Medical (ASX:ACW) has announced strategic collaboration with Oxford University researchers A
29 Nov 2021 The Sentiment Better than a sudoku: could this drug be the key to preventing Alzheimer’s?
15 Jul 2021 Stockhead These two ASX brain health stocks, boosted by FDA’s approval of Adulhelm, are kicking off clinical trials
15 Jul 2021 Biotech Daily Actinogen Enrols 1st XanaMIA Trial Patient
15 Jul 2021 The Market Herald Actinogen Medical (ASX:ACW) enrols first patient in Alzheimer’s Disease trial
15 Jul 2021 Monex Trading the World Here’s why the Actinogen (ASX:ACW) share price is rocketing 13% today
09 Jul 2021 Fragile X News Today FDA OKs Phase 2 Trial Design for Xanamem
23 Jun 2021 Stockhead Actinogen Medical gets a further boost from supportive FDA advice, shares up 7-fold in 2021
22 Jun 2021 The Motley Fool Here’s why the Actinogen Medical (ASX:ACW) share price is up 20%
21 Jun 2021 Biotech Daily Actinogen Appoints 2 CROs, Cogstate For XanaMIA
21 Jun 2021 The Market Herald Actinogen Medical (ASX:ACW) takes next step towards cortisol study
21 Jun 2021 Stockhead Dr Boreham’s Crucible: Time to make a song and dance about Actinogen (ASX:ACW)?
18 Jun 2021 Biotech Daily Dr Boreham’s Crucible: Actinogen Medical
16 Jun 2021 The Motley Fool Why is the Actinogen (ASX:ACW) share price up 414% in 3 months?
10 Jun 2021 Stockhead Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed
10 Jun 2021 Share Cafe Alzheimer’s Decision Sends Positive Message to Aussie Biotechs
08 Jun 2021 Stockhead FDA’s landmark approval of Biogen’s Alzheimer’s drug sends Cogstate up 60 per cent
04 Jun 2021 Stockhead Actinogen to progress Alzheimer’s study
02 Jun 2021 The Market Herald Actinogen Medical (ASX:ACW) granted ethics committee approval for Alzheimers study
02 Jun 2021 Biotech Daily Actinogen: Part-A Xanamia Xanamem Cognition Trial Approved
22 Apr 2021 Biotech Daily Actinogen Plans Three Phase II Cognition Trials For 2022
15 Apr 2021 The Motley Fool Actinogen (ASX:ACW) share price surges 23% today, 165% this year
15 Mar 2021 Biotech Daily Actinogen Appoints Dr Steven Gourlay CEO On $400k
15 Mar 2021 The Market Herald Actinogen Medical (ASX:ACW) appoints new CEO
11 Feb 2021 Biotech Daily Actinogen Shortfall Raises $3.55m – Total $10.9m
05 Feb 2021 The Market Herald Actinogen (ASX:ACW) nabs FDA designation for Fragile X treatment
20 Nov 2020 Biotech Daily Dr Boreham’s Crucible: Actinogen Medical
13 Nov 2020 Biotech Daily Actinogen Rights Raise $1.4m Of Hoped-For $4.9m – Total $7.4m
09 Nov 2020 The Market Herald Actinogen Medical (ASX:ACW) files new patent applications
09 Nov 2020 The Motley Fool Actinogen Medical (ASX:ACW) share price jumps on patent news

Back
to top